TransMedics Group (TMDX) Financials

$87.18 +0.34 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$86.40 -0.78 (-0.89%)

As of 07:51 PM Eastern

Annual Income Statements for TransMedics Group

This table shows TransMedics Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-34	-29	-44	-36	-25	35
Consolidated Net Income / (Loss)	-34	-29	-44	-36	-25	35
Net Income / (Loss) Continuing Operations	-34	-29	-44	-36	-25	35
Total Pre-Tax Income	-34	-29	-44	-36	-27	36
Total Operating Income	-30	-26	-39	-31	-29	37
Total Gross Profit	14	17	21	65	154	262
Total Revenue	24	26	30	93	242	442
Operating Revenue	24	26	30	93	242	442
Total Cost of Revenue	9.74	9.00	9.10	28	88	179
Operating Cost of Revenue	9.74	9.00	9.10	28	88	179
Total Operating Expenses	43	43	61	97	183	225
Selling, General & Admin Expense	24	24	38	70	120	169
Research & Development Expense	20	19	22	27	63	56
Total Other Income / (Expense), net	-3.90	-2.33	-4.75	-4.73	2.06	-1.72
Interest Expense	4.35	3.99	3.87	3.73	11	14
Other Income / (Expense), net	0.45	1.65	-0.88	-1.00	13	13
Income Tax Expense	0.04	0.03	0.04	0.07	-1.64	0.32
Basic Earnings per Share	($2.36)	($1.16)	($1.60)	($1.23)	($0.77)	$1.07
Weighted Average Basic Shares Outstanding	14.20M	24.70M	27.62M	29.56M	32.52M	33.23M
Diluted Earnings per Share	($2.36)	($1.16)	($1.60)	($1.23)	($0.77)	$1.01
Weighted Average Diluted Shares Outstanding	14.20M	24.70M	27.62M	29.56M	32.52M	35.22M
Weighted Average Basic & Diluted Shares Outstanding	14.20M	24.70M	27.96M	32.20M	32.72M	33.66M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00	-	$0.00	$0.00

This table shows TransMedics Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-7.43	-6.72	-2.64	-1.00	-25	4.03	12	12	4.22	6.86
Consolidated Net Income / (Loss)	-7.43	-6.72	-2.64	-1.00	-25	4.03	12	12	4.22	6.86
Net Income / (Loss) Continuing Operations	-7.43	-6.72	-2.64	-1.00	-25	4.03	12	12	4.22	6.86
Total Pre-Tax Income	-7.41	-6.70	-2.63	-0.98	-27	3.86	12	12	4.25	6.99
Total Operating Income	-5.54	-6.78	-2.09	-0.91	-28	2.60	12	13	3.92	8.64
Total Gross Profit	18	21	29	37	41	48	60	69	61	72
Total Revenue	26	31	42	52	66	81	97	114	109	122
Operating Revenue	26	31	42	52	66	81	97	114	109	122
Total Cost of Revenue	7.57	11	13	16	26	33	37	45	48	50
Operating Cost of Revenue	7.57	11	13	16	26	33	37	45	48	50
Total Operating Expenses	24	27	31	38	69	45	48	57	57	63
Selling, General & Admin Expense	17	22	25	29	31	35	36	43	43	47
Research & Development Expense	6.81	5.76	5.87	8.29	38	11	11	14	14	16
Total Other Income / (Expense), net	-1.86	0.08	-0.54	-0.07	1.41	1.26	-0.03	-0.36	0.32	-1.66
Interest Expense	0.79	1.01	1.09	2.51	3.59	3.61	3.60	3.62	3.62	3.57
Other Income / (Expense), net	-1.08	1.09	0.56	2.43	5.00	4.87	3.57	3.27	3.94	1.92
Income Tax Expense	0.02	0.02	0.01	0.02	-1.51	-0.17	0.20	-0.04	0.03	0.13
Basic Earnings per Share	($0.25)	($0.19)	($0.08)	($0.03)	($0.78)	$0.12	$0.37	$0.37	$0.13	$0.20
Weighted Average Basic Shares Outstanding	30.23M	29.56M	32.26M	32.55M	32.61M	32.52M	32.76M	33.12M	33.44M	33.23M
Diluted Earnings per Share	($0.25)	($0.19)	($0.08)	($0.03)	($0.78)	$0.12	$0.35	$0.35	$0.12	$0.19
Weighted Average Diluted Shares Outstanding	30.23M	29.56M	32.26M	32.55M	32.61M	32.52M	34.68M	35.29M	35.68M	35.22M
Weighted Average Basic & Diluted Shares Outstanding	31.92M	32.20M	32.55M	32.63M	32.65M	32.72M	32.94M	33.36M	33.56M	33.66M

This table details how cash moves in and out of TransMedics Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-0.06	4.49	1.00	176	194	-58
Net Cash From Operating Activities	-32	-30	-29	-46	-13	49
Net Cash From Continuing Operating Activities	-32	-30	-29	-46	-13	49
Net Income / (Loss) Continuing Operations	-34	-29	-44	-36	-25	35
Consolidated Net Income / (Loss)	-34	-29	-44	-36	-25	35
Depreciation Expense	1.22	1.58	1.82	3.48	8.18	20
Amortization Expense	-0.21	0.63	1.36	0.38	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	1.87	1.86	9.18	13	50	39
Changes in Operating Assets and Liabilities, net	-1.63	-5.59	3.00	-27	-46	-45
Net Cash From Investing Activities	-61	-42	29	55	-194	-129
Net Cash From Continuing Investing Activities	-61	-42	29	55	-194	-129
Purchase of Property, Plant & Equipment	-0.17	-0.46	-3.52	-12	-152	-130
Acquisitions	-	-	0.00	0.00	-42	0.44
Purchase of Investments	-82	-122	-72	-10	0.00	0.00
Sale and/or Maturity of Investments	22	81	105	77	0.00	0.00
Net Cash From Financing Activities	93	76	1.39	168	400	23
Net Cash From Continuing Financing Activities	93	76	1.39	168	400	23
Repayment of Debt	0.00	-2.25	0.00	-36	0.00	0.00
Repurchase of Common Equity	-4.85	0.00	0.00	0.00	0.00	0.00
Issuance of Debt	-	0.00	0.00	59	445	0.00
Issuance of Common Equity	97	75	0.42	140	0.96	2.06
Other Financing Activities, net	0.20	2.48	0.97	5.11	-46	21
Effect of Exchange Rate Changes	-	0.80	-0.80	-1.02	0.19	-0.54
Cash Interest Paid	3.88	3.48	3.33	3.26	8.09	11

This table details how cash moves in and out of TransMedics Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	174	-3.28	-5.56	387	-155	-32	-45	13	-33	6.56
Net Cash From Operating Activities	-14	-4.04	-8.66	-5.80	-6.87	8.30	-3.44	26	6.86	20
Net Cash From Continuing Operating Activities	-14	-4.04	-8.66	-5.80	-6.87	8.30	-3.44	26	6.86	20
Net Income / (Loss) Continuing Operations	-7.43	-6.72	-2.64	-1.00	-25	4.03	12	12	4.22	6.86
Consolidated Net Income / (Loss)	-7.43	-6.72	-2.64	-1.00	-25	4.03	12	12	4.22	6.86
Depreciation Expense	0.89	1.29	1.29	1.39	1.89	3.61	4.30	4.60	5.18	5.68
Non-Cash Adjustments To Reconcile Net Income	4.30	2.73	4.08	5.66	34	6.35	8.16	8.75	8.71	13
Changes in Operating Assets and Liabilities, net	-12	-1.33	-11	-12	-17	-5.68	-28	0.18	-11	-5.83
Net Cash From Investing Activities	25	-2.76	-0.93	-1.38	-150	-42	-44	-24	-48	-14
Net Cash From Continuing Investing Activities	25	-2.76	-0.93	-1.38	-150	-42	-44	-24	-48	-14
Purchase of Property, Plant & Equipment	-2.93	-2.76	-0.93	-1.38	-108	-42	-44	-24	-48	-14
Net Cash From Financing Activities	164	3.07	3.96	394	1.52	0.92	3.19	11	7.86	1.19
Net Cash From Continuing Financing Activities	164	3.07	3.96	394	1.52	0.92	3.19	11	7.86	1.19
Other Financing Activities, net	1.44	3.23	3.57	-51	0.95	0.92	2.55	11	6.44	1.19
Effect of Exchange Rate Changes	-0.61	0.45	0.07	0.01	-0.18	0.29	-0.17	-0.06	0.39	-0.69

This table presents TransMedics Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Total Assets	42	105	152	135	277	706	804
Total Current Assets	35	100	147	119	252	511	497
Cash & Equivalents	20	20	25	26	201	395	337
Accounts Receivable	3.44	6.56	6.86	5.93	28	64	98
Inventories, net	9.28	11	12	15	21	44	47
Prepaid Expenses	1.84	1.54	2.33	5.46	2.90	8.03	16
Plant, Property, & Equipment, net	3.47	4.79	4.75	9.84	19	174	286
Total Noncurrent Assets	3.89	0.51	0.51	6.35	5.63	21	21
Goodwill	-	-	-	-	0.00	12	12
Intangible Assets	-	-	-	-	0.00	2.35	2.15
Other Noncurrent Operating Assets	3.89	0.51	0.51	6.35	5.63	7.11	7.19
Total Liabilities & Shareholders' Equity	42	105	152	135	277	706	804
Total Liabilities	48	51	48	67	90	569	575
Total Current Liabilities	13	16	12	23	24	55	60
Accounts Payable	4.72	7.25	1.21	6.65	3.34	13	10
Accrued Expenses	7.18	8.33	10	16	19	38	45
Current Deferred Revenue	0.66	0.54	0.26	0.25	0.24	1.96	1.74
Other Current Liabilities	-	-	-	0.00	1.44	2.04	2.73
Total Noncurrent Liabilities	35	35	36	44	66	514	516
Long-Term Debt	34	34	35	35	59	506	509
Other Noncurrent Operating Liabilities	0.90	-	-	8.60	7.42	7.71	6.25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-192	55	104	68	187	137	229
Total Preferred & Common Equity	-192	55	104	68	187	137	229
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-192	55	104	68	187	137	229
Common Stock	144	424	502	510	666	641	697
Retained Earnings	-336	-369	-398	-442	-479	-504	-468
Accumulated Other Comprehensive Income / (Loss)	-0.10	-0.00	-0.10	-0.19	-0.23	-0.20	-0.36

This table presents TransMedics Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	275	287	690	689	724	759	786
Total Current Assets	251	262	663	537	488	509	492
Cash & Equivalents	204	195	582	427	350	363	330
Accounts Receivable	22	39	48	61	82	81	90
Inventories, net	19	24	31	39	49	49	52
Prepaid Expenses	5.51	3.77	2.38	9.60	7.61	17	20
Plant, Property, & Equipment, net	18	19	20	131	214	229	272
Total Noncurrent Assets	5.32	6.20	7.74	21	21	20	21
Goodwill	-	-	-	12	12	12	12
Intangible Assets	-	-	-	2.41	2.30	2.25	2.20
Other Noncurrent Operating Assets	5.32	6.20	7.74	7.42	6.81	6.48	7.61
Total Liabilities & Shareholders' Equity	275	287	690	689	724	759	786
Total Liabilities	87	94	545	563	564	569	576
Total Current Liabilities	21	29	32	49	50	54	60
Accounts Payable	3.08	4.33	7.03	13	9.23	13	13
Accrued Expenses	16	23	23	32	37	38	42
Current Deferred Revenue	0.23	0.24	0.24	2.63	2.06	1.45	2.18
Other Current Liabilities	1.41	1.48	1.88	1.99	2.09	2.14	2.54
Total Noncurrent Liabilities	66	66	513	514	514	514	516
Long-Term Debt	59	59	505	505	507	508	509
Other Noncurrent Operating Liabilities	-	7.03	8.46	8.23	7.16	6.60	7.07
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	188	193	145	126	159	190	210
Total Preferred & Common Equity	188	193	145	126	159	190	210
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	188	193	145	126	159	190	210
Common Stock	660	674	628	634	651	669	685
Retained Earnings	-472	-481	-482	-508	-492	-479	-475
Accumulated Other Comprehensive Income / (Loss)	-0.25	-0.22	-0.22	-0.26	-0.18	-0.24	-0.23

This table displays calculated financial ratios and metrics derived from TransMedics Group's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	8.62%	18.03%	208.83%	158.53%	82.74%
EBITDA Growth	0.00%	19.96%	-64.88%	23.03%	73.05%	1,008.05%
EBIT Growth	0.00%	15.17%	-62.97%	19.52%	51.05%	416.05%
NOPAT Growth	0.00%	10.87%	-49.44%	20.27%	8.62%	284.82%
Net Income Growth	0.00%	14.31%	-53.80%	18.06%	30.92%	241.70%
EPS Growth	0.00%	50.85%	-37.93%	23.13%	37.40%	231.17%
Operating Cash Flow Growth	0.00%	6.26%	4.63%	-58.73%	71.57%	474.60%
Free Cash Flow Firm Growth	0.00%	0.00%	-8.70%	-122.58%	-297.57%	48.39%
Invested Capital Growth	0.00%	59.20%	-17.88%	323.52%	453.80%	61.41%
Revenue Q/Q Growth	0.00%	0.00%	7.23%	30.25%	25.96%	10.09%
EBITDA Q/Q Growth	0.00%	-1,395.74%	-20.65%	18.57%	66.78%	7.98%
EBIT Q/Q Growth	0.00%	0.00%	-18.68%	15.56%	45.32%	6.57%
NOPAT Q/Q Growth	0.00%	0.00%	-15.98%	12.64%	24.62%	18.21%
Net Income Q/Q Growth	0.00%	0.00%	-16.79%	14.10%	30.05%	8.66%
EPS Q/Q Growth	0.00%	0.00%	-19.40%	17.45%	28.70%	7.45%
Operating Cash Flow Q/Q Growth	0.00%	0.41%	1.67%	5.40%	48.64%	30.34%
Free Cash Flow Firm Q/Q Growth	0.00%	-428.41%	-9.08%	11.57%	-22.81%	24.08%
Invested Capital Q/Q Growth	-56.05%	13.60%	-1.42%	-8.80%	21.39%	3.32%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	58.73%	64.88%	69.92%	69.84%	63.77%	59.36%
EBITDA Margin	-119.20%	-87.83%	-122.70%	-30.58%	-3.19%	15.84%
Operating Margin	-125.42%	-102.91%	-130.29%	-33.64%	-11.89%	8.49%
EBIT Margin	-123.51%	-96.46%	-133.19%	-34.71%	-6.57%	11.37%
Profit (Net Income) Margin	-142.12%	-112.13%	-146.11%	-38.77%	-10.36%	8.03%
Tax Burden Percent	100.12%	100.11%	100.08%	100.18%	93.84%	99.12%
Interest Burden Percent	114.93%	116.11%	109.61%	111.49%	167.95%	71.29%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.88%
Return on Invested Capital (ROIC)	-255.61%	-175.78%	-234.84%	-79.32%	-13.70%	11.44%
ROIC Less NNEP Spread (ROIC-NNEP)	-228.05%	-160.84%	-212.42%	-65.07%	17.94%	10.24%
Return on Net Nonoperating Assets (RNNOA)	194.22%	139.52%	183.35%	50.93%	-1.72%	7.95%
Return on Equity (ROE)	-61.39%	-36.27%	-51.49%	-28.39%	-15.42%	19.39%
Cash Return on Invested Capital (CROIC)	0.00%	-221.46%	-215.21%	-202.91%	-152.52%	-35.55%
Operating Return on Assets (OROA)	-39.54%	-19.22%	-28.10%	-15.75%	-3.23%	6.65%
Return on Assets (ROA)	-45.50%	-22.34%	-30.82%	-17.59%	-5.09%	4.70%
Return on Common Equity (ROCE)	172.63%	-36.27%	-51.49%	-28.39%	-15.42%	19.39%
Return on Equity Simple (ROE_SIMPLE)	-61.39%	-27.67%	-65.16%	-19.34%	-18.24%	15.51%
Net Operating Profit after Tax (NOPAT)	-21	-18	-28	-22	-20	37
NOPAT Margin	-87.79%	-72.03%	-91.20%	-23.55%	-8.32%	8.42%
Net Nonoperating Expense Percent (NNEP)	-27.56%	-14.95%	-22.42%	-14.24%	-31.64%	1.20%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-8.94%	-3.13%	5.04%
Cost of Revenue to Revenue	41.27%	35.12%	30.08%	30.16%	36.23%	40.64%
SG&A Expenses to Revenue	99.97%	94.34%	126.51%	74.79%	49.48%	38.19%
R&D to Revenue	84.18%	73.45%	73.70%	28.69%	26.18%	12.68%
Operating Expenses to Revenue	184.15%	167.79%	200.21%	103.48%	75.66%	50.86%
Earnings before Interest and Taxes (EBIT)	-29	-25	-40	-32	-16	50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-28	-23	-37	-29	-7.70	70
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	7.20	5.20	7.84	10.52	18.78	9.15
Price to Tangible Book Value (P/TBV)	7.20	5.20	7.84	10.52	20.97	9.74
Price to Revenue (P/Rev)	16.67	21.08	17.58	21.08	10.66	4.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	59.01
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	1.69%
Enterprise Value to Invested Capital (EV/IC)	42.79	34.83	44.80	40.72	10.81	5.65
Enterprise Value to Revenue (EV/Rev)	14.70	17.53	15.69	19.56	11.13	5.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	32.38
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	45.13
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	60.95
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	46.42
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.62	0.33	0.52	0.31	3.69	2.23
Long-Term Debt to Equity	0.62	0.33	0.52	0.31	3.69	2.23
Financial Leverage	-0.85	-0.87	-0.86	-0.78	-0.10	0.78
Leverage Ratio	3.01	1.62	1.67	1.61	3.03	4.13
Compound Leverage Factor	3.46	1.88	1.83	1.80	5.09	2.94
Debt to Total Capital	38.45%	25.01%	34.15%	23.85%	78.68%	69.02%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	38.45%	25.01%	34.15%	23.85%	78.68%	69.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	61.55%	74.99%	65.85%	76.15%	21.32%	30.98%
Debt to EBITDA	-1.21	-1.54	-0.95	-2.05	-65.72	7.28
Net Debt to EBITDA	1.65	4.04	1.54	4.99	-14.46	2.47
Long-Term Debt to EBITDA	-1.21	-1.54	-0.95	-2.05	-65.72	7.28
Debt to NOPAT	-1.65	-1.88	-1.28	-2.67	-25.17	13.70
Net Debt to NOPAT	2.25	4.93	2.07	6.47	-5.54	4.65
Long-Term Debt to NOPAT	-1.65	-1.88	-1.28	-2.67	-25.17	13.70
Altman Z-Score	0.01	3.77	0.26	11.69	2.76	2.77
Noncontrolling Interest Sharing Ratio	381.23%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	6.21	12.36	5.11	10.66	9.30	8.30
Quick Ratio	5.41	11.15	4.23	9.67	8.34	7.25
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-23	-25	-56	-224	-116
Operating Cash Flow to CapEx	-19,567.27%	-6,651.65%	-820.23%	-384.79%	-8.58%	37.61%
Free Cash Flow to Firm to Interest Expense	0.00	-5.84	-6.53	-15.11	-20.74	-8.02
Operating Cash Flow to Interest Expense	-7.42	-7.59	-7.45	-12.30	-1.21	3.39
Operating Cash Flow Less CapEx to Interest Expense	-7.45	-7.71	-8.36	-15.49	-15.28	-5.62
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.32	0.20	0.21	0.45	0.49	0.58
Accounts Receivable Turnover	4.72	3.82	4.73	5.57	5.30	5.47
Inventory Turnover	0.95	0.78	0.68	1.59	2.70	3.95
Fixed Asset Turnover	5.71	5.37	4.15	6.43	2.50	1.92
Accounts Payable Turnover	1.63	2.13	2.32	5.64	10.90	15.60
Days Sales Outstanding (DSO)	77.29	95.55	77.18	65.50	68.87	66.67
Days Inventory Outstanding (DIO)	383.94	469.22	537.16	229.62	135.19	92.33
Days Payable Outstanding (DPO)	224.20	171.33	157.52	64.69	33.48	23.40
Cash Conversion Cycle (CCC)	237.03	393.44	456.82	230.43	170.58	135.60
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	8.11	13	11	45	249	401
Invested Capital Turnover	2.91	2.44	2.57	3.37	1.65	1.36
Increase / (Decrease) in Invested Capital	0.00	4.80	-2.31	34	204	153
Enterprise Value (EV)	347	450	475	1,828	2,688	2,265
Market Capitalization	393	541	532	1,970	2,577	2,093
Book Value per Share	$2.58	$3.83	$2.44	$5.87	$4.20	$6.81
Tangible Book Value per Share	$2.58	$3.83	$2.44	$5.87	$3.76	$6.40
Total Capital	89	139	103	246	643	738
Total Debt	34	35	35	59	506	509
Total Long-Term Debt	34	35	35	59	506	509
Net Debt	-47	-91	-57	-142	111	173
Capital Expenditures (CapEx)	0.17	0.46	3.52	12	152	130
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3.20	9.25	3.02	27	61	101
Debt-free Net Working Capital (DFNWC)	84	135	95	229	456	437
Net Working Capital (NWC)	84	135	95	229	456	437
Net Nonoperating Expense (NNE)	13	10	17	14	4.92	1.70
Net Nonoperating Obligations (NNO)	-47	-91	-57	-142	111	173
Total Depreciation and Amortization (D&A)	1.02	2.21	3.17	3.86	8.18	20
Debt-free, Cash-free Net Working Capital to Revenue	13.55%	36.06%	9.96%	29.37%	25.21%	22.80%
Debt-free Net Working Capital to Revenue	355.39%	526.10%	315.47%	244.63%	188.61%	99.04%
Net Working Capital to Revenue	355.39%	526.10%	315.47%	244.63%	188.61%	99.04%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.16)	($1.60)	($1.23)	($0.77)	$1.07
Adjusted Weighted Average Basic Shares Outstanding	0.00	27.37M	27.62M	29.56M	32.52M	33.23M
Adjusted Diluted Earnings per Share	$0.00	($1.16)	($1.60)	($1.23)	($0.77)	$1.01
Adjusted Weighted Average Diluted Shares Outstanding	0.00	27.37M	27.62M	29.56M	32.52M	35.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.16)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	24.70M	27.96M	32.20M	32.72M	33.66M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-18	-28	-22	-20	37
Normalized NOPAT Margin	-87.79%	-72.03%	-91.20%	-23.55%	-8.32%	8.42%
Pre Tax Income Margin	-141.95%	-112.00%	-145.99%	-38.70%	-11.04%	8.10%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-6.70	-6.21	-10.40	-8.71	-1.47	3.48
NOPAT to Interest Expense	-4.76	-4.63	-7.12	-5.91	-1.86	2.58
EBIT Less CapEx to Interest Expense	-6.74	-6.32	-11.31	-11.90	-15.54	-5.52
NOPAT Less CapEx to Interest Expense	-4.80	-4.75	-8.03	-9.10	-15.94	-6.43
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-14.45%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from TransMedics Group's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	378.27%	224.52%	161.68%	155.66%	158.65%	158.72%	133.07%	117.87%	63.72%	49.83%
EBITDA Growth	49.01%	59.65%	97.21%	130.41%	-275.13%	351.15%	8,315.79%	598.49%	160.80%	46.66%
EBIT Growth	44.71%	51.22%	84.01%	114.48%	-252.55%	231.16%	1,142.44%	934.49%	133.69%	41.40%
NOPAT Growth	52.72%	40.16%	77.70%	90.70%	-411.09%	157.24%	935.98%	2,078.90%	119.64%	212.23%
Net Income Growth	42.71%	46.95%	75.04%	91.31%	-242.34%	159.99%	562.71%	1,318.18%	116.58%	70.11%
EPS Growth	46.81%	57.78%	78.95%	92.68%	-212.00%	163.16%	537.50%	1,266.67%	115.38%	58.33%
Operating Cash Flow Growth	-52.75%	39.31%	52.94%	36.19%	51.91%	305.80%	60.34%	543.18%	199.84%	136.79%
Free Cash Flow Firm Growth	-457.36%	-594.26%	-11.95%	-3.91%	-314.15%	-414.89%	-844.11%	-687.36%	-2.44%	28.26%
Invested Capital Growth	357.79%	323.52%	79.36%	88.18%	316.04%	453.80%	464.17%	394.88%	89.64%	61.41%
Revenue Q/Q Growth	25.15%	22.16%	32.44%	26.26%	26.62%	22.19%	19.31%	18.02%	-4.85%	11.83%
EBITDA Q/Q Growth	40.40%	22.88%	94.40%	1,280.97%	-835.21%	151.63%	83.27%	0.40%	-36.00%	24.55%
EBIT Q/Q Growth	37.13%	13.99%	73.06%	199.41%	-1,630.43%	132.00%	114.13%	-1.34%	-50.16%	34.32%
NOPAT Q/Q Growth	43.11%	-22.28%	69.18%	56.63%	-3,027.48%	113.69%	350.06%	2.66%	-68.96%	117.67%
Net Income Q/Q Growth	35.56%	9.51%	60.77%	62.03%	-2,439.66%	115.86%	202.58%	-0.02%	-65.43%	62.64%
EPS Q/Q Growth	39.02%	24.00%	57.89%	62.50%	-2,500.00%	115.38%	191.67%	0.00%	-65.71%	58.33%
Operating Cash Flow Q/Q Growth	-57.05%	71.75%	-114.65%	33.00%	-18.35%	220.91%	-141.37%	848.70%	-73.34%	186.76%
Free Cash Flow Firm Q/Q Growth	-36.06%	7.83%	32.72%	-23.16%	-442.26%	-14.59%	-23.37%	-2.71%	29.45%	19.75%
Invested Capital Q/Q Growth	36.88%	-8.80%	24.87%	20.73%	202.61%	21.39%	27.21%	5.90%	15.96%	3.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	70.53%	65.99%	69.23%	70.03%	61.21%	59.04%	61.91%	60.59%	55.94%	59.21%
EBITDA Margin	-22.26%	-14.05%	-0.59%	5.56%	-32.28%	13.64%	20.95%	17.83%	11.99%	13.35%
Operating Margin	-21.59%	-21.61%	-5.03%	-1.73%	-42.65%	3.21%	12.83%	10.94%	3.61%	7.11%
EBIT Margin	-25.78%	-18.15%	-3.69%	2.91%	-35.13%	9.20%	16.51%	13.80%	7.23%	8.68%
Profit (Net Income) Margin	-28.91%	-21.42%	-6.34%	-1.91%	-38.27%	4.97%	12.59%	10.67%	3.88%	5.64%
Tax Burden Percent	100.26%	100.28%	100.42%	102.14%	94.40%	104.35%	98.42%	100.34%	99.32%	98.11%
Interest Burden Percent	111.89%	117.69%	171.12%	-64.26%	115.38%	51.73%	77.50%	77.03%	53.99%	66.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	-4.35%	1.58%	-0.34%	0.68%	1.89%
Return on Invested Capital (ROIC)	-36.16%	-50.95%	-9.60%	-3.52%	-45.10%	5.51%	20.13%	19.57%	4.84%	9.48%
ROIC Less NNEP Spread (ROIC-NNEP)	-32.72%	-48.97%	-8.18%	-2.73%	-26.57%	-2.95%	19.86%	18.51%	5.09%	8.33%
Return on Net Nonoperating Assets (RNNOA)	25.35%	38.32%	5.35%	1.29%	5.10%	0.28%	1.14%	3.73%	3.89%	6.47%
Return on Equity (ROE)	-10.80%	-12.62%	-4.25%	-2.24%	-40.00%	5.79%	21.27%	23.30%	8.73%	15.95%
Cash Return on Invested Capital (CROIC)	-212.29%	-202.91%	-95.55%	-81.89%	-143.49%	-152.52%	-145.12%	-133.57%	-51.30%	-35.55%
Operating Return on Assets (OROA)	-9.11%	-8.23%	-2.14%	1.09%	-13.98%	4.52%	9.70%	6.83%	3.93%	5.08%
Return on Assets (ROA)	-10.22%	-9.72%	-3.68%	-0.71%	-15.23%	2.44%	7.40%	5.28%	2.11%	3.30%
Return on Common Equity (ROCE)	-10.80%	-12.62%	-4.25%	-2.24%	-40.00%	5.79%	21.27%	23.30%	8.73%	15.95%
Return on Equity Simple (ROE_SIMPLE)	-22.45%	0.00%	-14.69%	-12.25%	-28.29%	0.00%	-6.39%	1.58%	15.55%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.88	-4.75	-1.46	-0.63	-20	2.72	12	13	3.90	8.48
NOPAT Margin	-15.11%	-15.12%	-3.52%	-1.21%	-29.86%	3.35%	12.62%	10.98%	3.58%	6.97%
Net Nonoperating Expense Percent (NNEP)	-3.43%	-1.98%	-1.42%	-0.79%	-18.53%	8.46%	0.27%	1.06%	-0.25%	1.14%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.93%	-	-	-	0.42%	-	-	-	1.15%
Cost of Revenue to Revenue	29.47%	34.01%	30.77%	29.97%	38.79%	40.96%	38.09%	39.41%	44.06%	40.79%
SG&A Expenses to Revenue	65.61%	69.25%	60.12%	55.95%	46.14%	42.58%	37.34%	37.53%	39.22%	38.57%
R&D to Revenue	26.51%	18.35%	14.13%	15.80%	57.72%	13.26%	11.75%	12.12%	13.12%	13.54%
Operating Expenses to Revenue	92.12%	87.59%	74.25%	71.76%	103.86%	55.83%	49.09%	49.65%	52.34%	52.10%
Earnings before Interest and Taxes (EBIT)	-6.62	-5.69	-1.53	1.53	-23	7.47	16	16	7.86	11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.72	-4.41	-0.25	2.92	-21	11	20	20	13	16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.24	10.52	12.66	18.83	14.13	18.78	15.14	26.13	24.95	9.15
Price to Tangible Book Value (P/TBV)	6.24	10.52	12.66	18.83	15.90	20.97	16.63	28.17	26.70	9.74
Price to Revenue (P/Rev)	16.34	21.08	20.47	18.10	9.31	10.66	8.13	13.83	13.06	4.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,653.67	160.47	59.01
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.62%	1.69%
Enterprise Value to Invested Capital (EV/IC)	21.01	40.72	41.06	39.25	9.11	10.81	8.13	15.25	13.95	5.65
Enterprise Value to Revenue (EV/Rev)	14.41	19.56	19.32	17.58	9.72	11.13	8.66	14.23	13.50	5.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	200.26	168.54	83.60	32.38
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	1,562.75	321.21	114.99	45.13
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	172.26	60.95
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	215.27	144.64	46.42
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.35	0.31	0.31	3.48	4.00	3.69	3.18	2.67	2.42	2.23
Long-Term Debt to Equity	0.35	0.31	0.31	3.48	4.00	3.69	3.18	2.67	2.42	2.23
Financial Leverage	-0.77	-0.78	-0.65	-0.47	-0.19	-0.10	0.06	0.20	0.76	0.78
Leverage Ratio	1.52	1.61	1.63	4.12	3.07	3.03	2.87	4.32	4.38	4.13
Compound Leverage Factor	1.71	1.90	2.79	-2.65	3.54	1.57	2.23	3.33	2.37	2.73
Debt to Total Capital	26.09%	23.85%	23.39%	77.66%	79.99%	78.68%	76.07%	72.78%	70.78%	69.02%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	26.09%	23.85%	23.39%	77.66%	79.99%	78.68%	76.07%	72.78%	70.78%	69.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	73.91%	76.15%	76.61%	22.34%	20.01%	21.32%	23.93%	27.22%	29.22%	30.98%
Debt to EBITDA	-1.89	-2.05	-2.95	-67.58	-21.80	-65.72	39.49	16.76	7.85	7.28
Net Debt to EBITDA	3.95	4.99	6.84	10.38	-3.38	-14.46	12.21	4.79	2.75	2.47
Long-Term Debt to EBITDA	-1.89	-2.05	-2.95	-67.58	-21.80	-65.72	39.49	16.76	7.85	7.28
Debt to NOPAT	-2.63	-2.67	-3.48	-47.07	-18.95	-25.17	-50.94	-311.94	16.17	13.70
Net Debt to NOPAT	5.50	6.47	8.08	7.23	-2.94	-5.54	-15.75	-89.08	5.68	4.65
Long-Term Debt to NOPAT	-2.63	-2.67	-3.48	-47.07	-18.95	-25.17	-50.94	-311.94	16.17	13.70
Altman Z-Score	6.87	12.01	14.51	3.35	1.89	2.87	2.83	5.61	5.82	2.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.11	10.66	9.14	20.70	10.93	9.30	9.72	9.37	8.20	8.30
Quick Ratio	10.95	9.67	8.17	19.67	9.93	8.34	8.60	8.17	7.00	7.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-42	-39	-26	-32	-175	-201	-248	-255	-180	-144
Operating Cash Flow to CapEx	-487.44%	-145.98%	-934.30%	-420.51%	-6.38%	19.86%	-7.78%	108.23%	14.23%	144.52%
Free Cash Flow to Firm to Interest Expense	-53.81	-38.76	-24.07	-12.91	-48.86	-55.75	-68.91	-70.29	-49.68	-40.38
Operating Cash Flow to Interest Expense	-18.15	-4.01	-7.94	-2.32	-1.91	2.30	-0.95	7.10	1.90	5.51
Operating Cash Flow Less CapEx to Interest Expense	-21.87	-6.75	-8.79	-2.87	-31.92	-9.30	-13.23	0.54	-11.43	1.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.45	0.58	0.37	0.40	0.49	0.59	0.50	0.54	0.58
Accounts Receivable Turnover	5.48	5.57	4.73	4.99	4.64	5.30	4.93	5.58	5.32	5.47
Inventory Turnover	1.21	1.59	1.83	1.95	2.24	2.70	3.08	3.56	3.56	3.95
Fixed Asset Turnover	6.10	6.43	7.64	8.36	2.57	2.50	2.54	2.88	1.99	1.92
Accounts Payable Turnover	7.01	5.64	10.24	7.34	8.16	10.90	16.47	14.05	12.56	15.60
Days Sales Outstanding (DSO)	66.60	65.50	77.12	73.09	78.67	68.87	74.10	65.46	68.61	66.67
Days Inventory Outstanding (DIO)	302.20	229.62	199.55	187.42	162.80	135.19	118.53	102.57	102.40	92.33
Days Payable Outstanding (DPO)	52.07	64.69	35.63	49.74	44.72	33.48	22.16	25.97	29.06	23.40
Cash Conversion Cycle (CCC)	316.74	230.43	241.04	210.77	196.75	170.58	170.48	142.06	141.95	135.60
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	49	45	56	68	205	249	316	335	388	401
Invested Capital Turnover	2.39	3.37	2.73	2.92	1.51	1.65	1.60	1.78	1.35	1.36
Increase / (Decrease) in Invested Capital	38	34	25	32	156	204	260	267	184	153
Enterprise Value (EV)	1,034	1,828	2,302	2,656	1,865	2,688	2,571	5,106	5,416	2,265
Market Capitalization	1,173	1,970	2,438	2,734	1,787	2,577	2,414	4,961	5,237	2,093
Book Value per Share	$6.69	$5.87	$5.98	$4.46	$3.88	$4.20	$4.87	$5.77	$6.29	$6.81
Tangible Book Value per Share	$6.69	$5.87	$5.98	$4.46	$3.44	$3.76	$4.43	$5.35	$5.88	$6.40
Total Capital	254	246	251	650	632	643	666	698	718	738
Total Debt	66	59	59	505	505	506	507	508	509	509
Total Long-Term Debt	66	59	59	505	505	506	507	508	509	509
Net Debt	-139	-142	-137	-78	78	111	157	145	178	173
Capital Expenditures (CapEx)	2.93	2.76	0.93	1.38	108	42	44	24	48	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	25	27	38	48	61	61	88	92	102	101
Debt-free Net Working Capital (DFNWC)	230	229	233	631	488	456	438	455	432	437
Net Working Capital (NWC)	230	229	233	631	488	456	438	455	432	437
Net Nonoperating Expense (NNE)	3.55	1.97	1.17	0.37	5.59	-1.31	0.03	0.36	-0.32	1.62
Net Nonoperating Obligations (NNO)	-139	-142	-137	-78	78	111	157	145	178	173
Total Depreciation and Amortization (D&A)	0.90	1.29	1.29	1.39	1.89	3.61	4.30	4.60	5.18	5.68
Debt-free, Cash-free Net Working Capital to Revenue	34.75%	29.37%	31.66%	32.06%	31.55%	25.21%	29.59%	25.70%	25.51%	22.80%
Debt-free Net Working Capital to Revenue	320.41%	244.63%	195.66%	417.43%	254.20%	188.61%	147.54%	126.81%	107.81%	99.04%
Net Working Capital to Revenue	320.41%	244.63%	195.66%	417.43%	254.20%	188.61%	147.54%	126.81%	107.81%	99.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.25)	($0.19)	($0.08)	($0.03)	($0.78)	$0.12	$0.37	$0.37	$0.13	$0.20
Adjusted Weighted Average Basic Shares Outstanding	30.23M	29.56M	32.26M	32.55M	32.61M	32.52M	32.76M	33.12M	33.44M	33.23M
Adjusted Diluted Earnings per Share	($0.25)	($0.19)	($0.08)	($0.03)	($0.78)	$0.12	$0.35	$0.35	$0.12	$0.19
Adjusted Weighted Average Diluted Shares Outstanding	30.23M	29.56M	32.26M	32.55M	32.61M	32.52M	34.68M	35.29M	35.68M	35.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	31.92M	32.20M	32.55M	32.63M	32.65M	32.72M	32.94M	33.36M	33.56M	33.66M
Normalized Net Operating Profit after Tax (NOPAT)	-3.88	-4.75	-1.46	-0.63	-20	1.82	12	8.76	3.90	8.48
Normalized NOPAT Margin	-15.11%	-15.12%	-3.52%	-1.21%	-29.86%	2.24%	12.62%	7.66%	3.58%	6.97%
Pre Tax Income Margin	-28.84%	-21.36%	-6.32%	-1.87%	-40.54%	4.76%	12.80%	10.63%	3.90%	5.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.41	-5.65	-1.41	0.61	-6.50	2.07	4.44	4.35	2.17	2.96
NOPAT to Interest Expense	-4.93	-4.71	-1.34	-0.25	-5.52	0.75	3.40	3.46	1.08	2.37
EBIT Less CapEx to Interest Expense	-12.13	-8.40	-2.26	0.06	-36.51	-9.53	-7.83	-2.20	-11.15	-0.85
NOPAT Less CapEx to Interest Expense	-8.65	-7.46	-2.19	-0.80	-35.53	-10.85	-8.88	-3.09	-12.25	-1.44
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About TransMedics Group's Financials

When does TransMedics Group's financial year end?

According to the most recent income statement we have on file, TransMedics Group's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has TransMedics Group's net income changed over the last 5 years?

TransMedics Group's net income appears to be on a downward trend, with a most recent value of $35.46 million in 2024, falling from -$33.55 million in 2019. The previous period was -$25.03 million in 2023.

What is TransMedics Group's operating income?

TransMedics Group's total operating income in 2024 was $37.50 million, based on the following breakdown:

Total Gross Profit: $262.08 million
Total Operating Expenses: $224.59 million

How has TransMedics Group revenue changed over the last 5 years?

Over the last 5 years, TransMedics Group's total revenue changed from $23.60 million in 2019 to $441.54 million in 2024, a change of 1,770.6%.

How much debt does TransMedics Group have?

TransMedics Group's total liabilities were at $575.47 million at the end of 2024, a 1.2% increase from 2023, and a 1,101.9% increase since 2018.

How much cash does TransMedics Group have?

In the past 6 years, TransMedics Group's cash and equivalents has ranged from $20.09 million in 2019 to $394.81 million in 2023, and is currently $336.65 million as of their latest financial filing in 2024.

How has TransMedics Group's book value per share changed over the last 5 years?

Over the last 5 years, TransMedics Group's book value per share changed from 2.58 in 2019 to 6.81 in 2024, a change of 163.8%.

Remove Ads

Related Companies

This page (NASDAQ:TMDX) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Financials

Frequently Asked Questions About TransMedics Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransMedics Group (TMDX) Financials

Annual Income Statements for TransMedics Group

Quarterly Income Statements for TransMedics Group

Annual Cash Flow Statements for TransMedics Group

Quarterly Cash Flow Statements for TransMedics Group

Annual Balance Sheets for TransMedics Group

Quarterly Balance Sheets for TransMedics Group

Annual Metrics and Ratios for TransMedics Group

Quarterly Metrics and Ratios for TransMedics Group

Frequently Asked Questions About TransMedics Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools